Mike Doustdar

Mike Doustdar, the new CEO of Novo Nordisk, shares insights on his first months at the helm, focusing on the challenge of reclaiming market share in obesity treatments. He discusses a patient-first acquisition strategy and Novo’s recent $10B bid for Metsera. Venture capitalist Bob Nelsen reflects on the importance of relationships in biotech at the J.P. Morgan conference, advocating for faster FDA approvals and the integration of AI in healthcare. Both guests offer exciting glimpses into the future of biotech and the evolving landscape of patient care.

Mike Doustdar, CEO of Novo Nordisk, leads the charge in obesity and diabetes treatments. He shares insights on the launch of an oral version of their popular weight loss drug Wegovy, highlighting its early success and unique formulation. Doustdar delves into the competitive landscape, discussing how their pill offers advantages over others. He also emphasizes the significance of scaling production and innovative pricing strategies. Lastly, he explores the transformative role of AI in accelerating drug discovery and improving patient access.

Mike Doustdar, the CEO of Novo Nordisk, shares insights on the recent US approval of the Wegovy weight-loss pill, emphasizing its first-mover advantage. He discusses how the pill’s efficacy data compares with competitors and the strategic rollout plans involving various sales channels. Doustdar addresses supply concerns, highlighting R&D breakthroughs that ensure production scalability and affordability. He also touches on the potential market expansion by attracting patients who prefer pills over injections, and the company's ambitions for growth through acquisitions.